Identification and validation of inferior prognostic genes associated with immune signatures and chemotherapy outcome in acute myeloid leukemia

Wang, Jie; Jian-ping, Hao; Uddin, Nazim; Wu, Yun; Chen, Rong; Li, Dongfeng; Ding, Nan; Yang, Jianhua; Ding, Xiaowen

doi:10.18632/aging.203166

Cited by 11 publications

(6 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6f ). IC-lncRNA ITGB2-AS1 is antisense to ITGB2 and has been shown to be highly expressed, and closely related to immunosuppression in AML 44 . ITGB2-AS1 may be used as a potential immunotherapeutic target in cancers.…”

Section: Resultsmentioning

confidence: 99%

Surveying lncRNA-lncRNA cooperations reveals dominant effect on tumor immunity cross cancers

et al. 2022

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) can crosstalk with each other by post-transcriptionally co-regulating genes involved in the same or similar functions; however, the regulatory principles and biological insights in tumor-immune are still unclear. Here, we show a multiple-step model to identify lncRNA-lncRNA immune cooperation based on co-regulating functional modules by integrating multi-omics data across 20 cancer types. Moreover, lncRNA immune cooperative networks (LICNs) are constructed, which are likely to modulate tumor-immune microenvironment by regulating immune-related functions. We highlight conserved and rewired network hubs which can regulate interactions between immune cells and tumor cells by targeting ligands and activating or inhibitory receptors such as PDCD1, CTLA4 and CD86. Immune cooperative lncRNAs (IC-lncRNAs) playing central roles in many cancers also tend to target known anticancer drug targets. In addition, these IC-lncRNAs tend to be highly expressed in immune cell populations and are significantly correlated with immune cell infiltration. The similar immune mechanisms cross cancers are revealed by the LICNs. Finally, we identify two subtypes of skin cutaneous melanoma with different immune context and prognosis based on IC-lncRNAs. In summary, this study contributes to a comprehensive understanding of the cooperative behaviours of lncRNAs and accelerating discovery of lncRNA-based biomarkers in cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Surveying lncRNA-lncRNA cooperations reveals dominant effect on tumor immunity cross cancers

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The ITGAM also plays an important role in the tumor microenvironment in leukemia cell activation, chemotaxis, and cytotoxicity [19]. Several studies have shown that the positive expression of ITGAM was closely associated with the prognosis of AML patients [20,21]. A previous study indicated that lncRNA ITGB2 was significantly associated with various immune signatures in AML [22].…”

Section: Discussionmentioning

confidence: 99%

HCK is a Potential Prognostic Biomarker that Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia

Cheng

Wang

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Background. The tumor microenvironment (TME) plays a significant role in the progression and prognosis of acute myeloid leukemia (AML). This study is aimed at exploring TME-associated biomarkers and identify their potential mechanism in the microenvironment of AML. Method. In this study, the stromal, immune, and ESTIMATE scores of AML patients were evaluated with the ESTIMATE and CIBERSORT algorithms; then, the AML samples were divided into high- and low-score groups. We evaluated the association between clinicopathological characteristics, survival rate, and the stromal/immune/ESTIMATE scores. Furthermore, we identified TME-associated differentially expressed genes (DEGs) then carried out pathway enrichment analysis, protein-protein interaction (PPI) network, Cox regression analysis, and Kaplan-Meier survival analysis to select the most crucial genes. In addition, we further explored the potential mechanism of HCK in the AML microenvironment. Results. We identified 624 TME-associated DEGs and found that HCK was the most promising biomarker associated with AML. The results of the gene set enrichment analysis (GSEA) indicated that HCK was mainly involved in immune and inflammation-related signaling pathways. In addition, CIBERSORT analysis showed that HCK was closely related to tumor immune infiltration, with HCK expression associated with various infiltrating immune cells, including B cells, T cells, tumor-associated macrophages (TAM), NK cells, plasma cells, eosinophils, and neutrophils. Furthermore, HCK expression was closely related with ELN risk stratification in patients with AML. Conclusion. HCK could regulate immune cell infiltration in the microenvironment of AML and may act as a potential biomarker for the treatment and prognosis of AML patients.

show abstract

“…ITGB2 and ITGAM have tissue specificity on BM [ 2 ] and take part in a portion of vital biological processes. For example, ITGB2 is involved in adhesion, migration of leukocytes [ 36 ] and immune response including NK cell-induced cytotoxicity [ 37 – 39 ]. From a bioinformatics analysis, ITGAM and ITGB2 were also up-regulated in myeloma and involved in cytokine-cytokine receptor interaction, innate immune response and inflammatory response that were similar to our results [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Systematic analysis of prognostic significance, functional enrichment and immune implication of STK10 in acute myeloid leukemia

Jia

et al. 2022

BMC Med Genomics

View full text Add to dashboard Cite

Background Despite deeper understanding of the genetic landscape of acute myeloid leukemia (AML), the improvement of survival is still a great challenge. STK10 is overexpressed in several cancers with functions varying according to cancer types. But the functions of STK10 in AML has never been reported. Methods We analyzed the expression, prognosis and potential functions of STK10 utilizing public web servers. Metascape and the String database were used for functional and protein–protein interaction analyses. Results We found STK10 was enriched in blood & immune cells and overexpressed in AML. High STK10 expression was associated with poor overall survival, which was also identified in the subgroups of patients ≤ 60 years old and patients with non-high-risk cytogenetics. We demonstrated genes associated with STK10 were enriched in blood, spleen and bone marrow, influencing the immune function and biological process of AML. ITGB2 and ITGAM might directly interact with STK10 and were associated with poor prognosis. Besides, STK10 was associated with the infiltration of immune cells and immune checkpoints, like HLA-E, CD274 and GAL-9. Conclusions The present study was the original description of STK10 in AML and set the stage for developing STK10 as a new prognostic marker or therapeutic target for AML.

show abstract

Identification and validation of inferior prognostic genes associated with immune signatures and chemotherapy outcome in acute myeloid leukemia

Cited by 11 publications

References 70 publications

Surveying lncRNA-lncRNA cooperations reveals dominant effect on tumor immunity cross cancers

Surveying lncRNA-lncRNA cooperations reveals dominant effect on tumor immunity cross cancers

HCK is a Potential Prognostic Biomarker that Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia

Systematic analysis of prognostic significance, functional enrichment and immune implication of STK10 in acute myeloid leukemia

Contact Info

Product

Resources

About